These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 10999504)

  • 1. Aldosterone, a new appreciation of its role in heart failure.
    Cha AJ; Malecha SE; Judge KW
    Pharmacotherapy; 2000 Sep; 20(9):1107-15. PubMed ID: 10999504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone and antialdosterone therapy in congestive heart failure.
    Weber KT; Villarreal D
    Am J Cardiol; 1993 Jan; 71(3):3A-11A. PubMed ID: 8422002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
    Miller AB; Srivastava P
    Cardiol Clin; 2001 May; 19(2):195-202, v. PubMed ID: 11407105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of aldosterone and aldosterone-receptor antagonists in heart failure.
    Khan NU; Movahed A
    Rev Cardiovasc Med; 2004; 5(2):71-81. PubMed ID: 15184841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The renin-angiotensin-aldosterone system and heart failure.
    Sayer G; Bhat G
    Cardiol Clin; 2014 Feb; 32(1):21-32, vii. PubMed ID: 24286576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Aldosterone and its antagonists in heart failure].
    Lopes ME; Le Corvoisier P; Tabet JY; Su JB; Badoual T; Cachin JC; Merlet P; Castaigne A; Hittinger L
    Presse Med; 2003 Jan; 32(2):79-87. PubMed ID: 12653034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
    Hameedi A; Chadow HL
    Curr Hypertens Rep; 2000 Aug; 2(4):378-83. PubMed ID: 10981173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
    Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treasures from old? EPHESUS. Eplerenome Post-AHI Heart Failure Efficacy and Survival Study.
    Pfeffer MA
    Cardiovasc Drugs Ther; 2001 Jan; 15(1):11-3. PubMed ID: 11504157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?
    Struthers AD
    Br J Clin Pharmacol; 1999 May; 47(5):479-82. PubMed ID: 10336570
    [No Abstract]   [Full Text] [Related]  

  • 12. [Aldosterone blockade in heart failure. So much for so little].
    González-Juanatey JR; Mazón Ramos P
    Med Clin (Barc); 2002 Jun; 118(20):779-81. PubMed ID: 12049694
    [No Abstract]   [Full Text] [Related]  

  • 13. [Decrease in mortality on spironolactone being added to the conventional treatment of heart failure].
    Soto Alvarez J
    Aten Primaria; 2000 Mar; 25(4):282-4. PubMed ID: 10795447
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
    Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
    Black HR
    Am Heart J; 2004 Apr; 147(4):564-72. PubMed ID: 15077068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novelties in Therapy of Chronic Heart Failure.
    Doimo S; Pavan D
    Heart Fail Clin; 2021 Apr; 17(2):255-262. PubMed ID: 33673949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spironolactone in heart failure--a revived role for an old drug.
    Bradley C
    Intensive Crit Care Nurs; 2000 Dec; 16(6):403-4. PubMed ID: 11091472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The SEISICAT study: a pilot study assessing efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy.
    James R; Guillot E; Garelli-Paar C; Huxley J; Grassi V; Cobb M
    J Vet Cardiol; 2018 Feb; 20(1):1-12. PubMed ID: 29277469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-blockers and spironolactone in heart failure.
    Kukin ML
    Curr Cardiol Rep; 2000 Mar; 2(2):87-9. PubMed ID: 10980877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Aldosterone antagonists for all patients with heart failure?].
    Bauersachs J
    MMW Fortschr Med; 2009 Apr; 151(15):33-5. PubMed ID: 19728679
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.